. Author manuscript; available in PMC: 2010 Aug 1.

Published in final edited form as: Cancer Gene Ther. 2009 Sep 18;17(2):86–96. doi: 10.1038/cgt.2009.60

Table 2.

In vivo response of rat C6 tumors expressing wild type HSVTK, mutant 30, MGMK/HSVTK or MGMK/30 to PBS or GCV treatment.

	Mean Tumor Volume (mm³)
	Day 8		Day 16
	PBS	GCV (1mg/kg)	GCV (1mg/kg)
HSVTK	428.29 (39.27)^a	453.42 (43.17)^**	3622.50 (242.60)^**
Mutant 30	399.30 (23.58)	126.19 (20.03)^**	1681.80 (248.88)^**
MGMK/HSVTK	438.51 (47.73)	109.85 (14.94)^**	1679.10 (284.62)^**
MGMK/30	473.76 (39.49)	16.60 (3.06)	33.39 (5.55)

Standard error mean

^**

P values ≤ 0.0001, this P values reflect a comparison between MGMK/30 and HSVTK, or between MGMK/30 and mutant 30, or between MGMK/30 and MGMK/HSVTK tumor sizes treated with GCV (1mg/kg) at two different time points (day 8 and day 16) (n=5).